CMPS:NASDAQ
Compass Pathways PLC
US$8.44
arrow_downward
-5.06%(-0.45) 1D
US$8.53
arrow_upward
+1.07% (+0.090)bedtime시간 외 거래
휴장: 4월 28일, 오후 4시 0분 1초 GMT-4 · USD
search
모든 종목 코드
1D
5D
1M
6M
YTD
1Y
5Y
최대
| 종목 코드 | 가격 | 변동 | 변동률(%) |
|---|
insights_autoCMPS의 주요 통계 생성 중...
시가
US$8.75
고가
US$8.97
저가
US$8.39
시가총액
11.39억
평균 거래량
376.18만
거래량
312.97만
52주 최고가
US$10.21
52주 최저가
US$2.25
EPS
-US$3.08
베타
2.01
유통 주식수
1.35억
직원 수
156
뉴스 기사
웹 소스 기반
프로필
Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin, is currently in phase 3 clinical trials for treatment-resistant depression. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration. It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine.
Compass Pathways is the largest company in the psychedelic medicine industry and, in 2020, was the first psychedelic medicine company to be listed on the NASDAQ. It has faced criticism for patenting psychedelic drugs and even certain psilocybin mushroom species. In October 2024, after the FDA rejected Lykos Therapeutics's MDMA for post-traumatic stress disorder New Drug Application, Compass Pathways said that it would lay off 30% of its workforce and narrow its research focus.
Compass Pathways has entered partnerships with several independent psychedelic academic scientists, including Jason Wallach, Hamilton Morris, and Adam Halberstadt among others, to develop novel psychedelic drugs for potential medical use. Wikipedia
Compass Pathways PLC에 관한 정보